Some posts may be temporarily unavailable
Geneva, Switzerland, October 2018. Following the recent successful financing of GBC-R1, a new molecule to treat allergic diseases (see also gbc-hpvac.com), and to support its other ongoing projects, the GBC is pleased to announce that Silvia Hansel has joined the GBC team as Chief of Operations. Silvia will manage the day-to-day activities of the GBC,…
Geneva, Switzerland, October 2018. GBC-HpVac SA has successfully concluded a seed financing round, which enables it to proceed with the lead validation phase of its molecule GBC-R1. The production of new batches of GBC-R1 started in early October at a trusted GMP site and sufficient DS is now available to supply the upcoming bioequivalence, dose…